Antares Pharma, Inc. (NASDAQ:ATRS) went up by 3.51% from its latest closing price when compared to the 1-year high value of $5.13 and move down -117.37%, while ATRS stocks collected +6.79% of gains with the last five trading sessions. Press Release reported on 03/03/20 that Antares Pharma Reports Fourth Quarter and Full Year 2019 Operating and Financial Results

Antares Pharma, Inc. (NASDAQ:ATRS) Worth an Investment?

Antares Pharma, Inc. (NASDAQ: ATRS) The 36 Months beta value for ATRS stocks is at 1.24, while of the analysts out of 0 who provided ratings for Antares Pharma, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell. ATRS currently has a short float of 4.63% and public float of 153.22M with average trading volume of 1.67M shares.

ATRS Market Performance

ATRS stocks went up by 6.79% for the week, with the monthly drop of -26.71% and a quarterly performance of -49.25%, while its annual performance rate touched -20.27%. The simple moving average for the period of the last 20 days is -6.33% for ATRS stocks with the simple moving average of -33.97% for the last 200 days.

Analysts’ Opinion on Antares Pharma, Inc. (NASDAQ:ATRS)

Many brokerage firms have already submitted their reports for ATRS stocks, with H.C. Wainwright repeating the rating for ATRS shares by setting it to “Buy”. The predicted price for ATRS socks in the upcoming period according to H.C. Wainwright is $3.50 based on the research report published on October 23, 2017.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see ATRS stock at the price of $5. The rating they have provided for ATRS stocks is “Buy” according to the report published on June 23, 2017.

Raymond James gave “Strong Buy” rating to ATRS stocks, setting the target price at $5 in the report published on April 21, 2017.

ATRS Stocks -26.48% Far from 50 Day Moving Average

After a stumble in the market that brought ATRS to its low price for the period of the last 52 weeks, Antares Pharma, Inc. was unable to take a rebound, for now settling with -54.00% of loss for the given period.

The stock volatility was left at 12.79%, however, within the period of a single month, the volatility rate increased by 10.35%, while the shares sank at the distance of -24.12% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -44.34% lower at the present time.

In the course of the last 5 trading sessions, ATRS went up by +6.79%, which changed the moving average for the period of 200 days to the total of -20.27% of losses for the stock in comparison to the 20-day moving average settled at $2.48. In addition, Antares Pharma, Inc. saw -49.79% in overturn over the period of a single year with a tendency to cut further losses.

ATRS Stock Insider Trading

Reports are indicating that there were more than several insider trading activities at Antares Pharma, Inc. (ATRS), starting from SAMSON MARVIN, who sold 56 shares at the price of $4.50 back on Jan 10. After this action, Rushing now owns 51,751 shares of Antares Pharma, Inc., valued at $252 with the latest closing price.

SAMSON MARVIN, the Director of Antares Pharma, Inc., sold 99,944 shares at the value of $4.59 during a trade that took place back on Jan 02, which means that SAMSON MARVIN is holding 51,751 shares at the value of $459,242 based on the most recent closing price.

ATRS Stock Fundamentals

The current profitability levels are settled at +0.80 for the present operating margin and +58.97 for gross margin. The net margin for Antares Pharma, Inc. stands at -1.64. Equity return holds the value -4.40%, with -1.70% for asset returns.

EBITDA value lies at +6.21 M with total debt to EBITDA carrying the value of 11.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.35.